Company news
Biomea Fusion, Inc. (NASDAQ:BMEA) news
Biomea Fusion, Inc. news releases on 6ix. Latest, Jul 1, 2022: Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study…
Press releases — page 3
Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219’s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes
June 30, 2022
Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial
June 21, 2022
Biomea Fusion to Present New Preclinical Data Showing BMF-219’s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022
May 25, 2022
Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3
May 18, 2022
Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights
May 15, 2022
Biomea Fusion Announces Acceptance of Multiple Abstracts at the 2022 ASCO Annual Meeting
April 26, 2022
Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting
April 7, 2022
Biomea Fusion Announces Acceptance of Late Breaking Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022
April 5, 2022
Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022
March 13, 2022
Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022
March 7, 2022
Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
February 27, 2022
Biomea Fusion Announces Appointment of Steve Morris, M.D. as Chief Medical Officer
January 31, 2022
Biomea Fusion Announces First Patient Dosed
January 24, 2022
Biomea Fusion Announces 2022 Clinical Development Plan to Initiate Studies in up to Seven Different Tumor Types and in Diabetes for BMF-219
January 9, 2022
Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes
January 5, 2022
Biomea Fusion Moves into New Headquarters and Expands R&D Facility
January 3, 2022
Biomea Fusion to be added to NASDAQ Biotechnology Index
December 13, 2021
Biomea Fusion Reports Third Quarter 2021 Financial Results and Business Highlights
November 2, 2021
Biomea Fusion Announces FDA Clearance of Investigational New Drug Application for Irreversible Menin Inhibitor BMF-219
September 15, 2021
Biomea Fusion Reports Second Quarter 2021 Financial Results and Business Highlights
August 10, 2021
BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer
June 27, 2021
Biomea Fusion Reports First Quarter 2021 Financial Results and Business Highlights
May 26, 2021
Biomea Announces Closing of Initial Public Offering
April 19, 2021
Biomea Announces Pricing of Initial Public Offering
April 14, 2021